Advice

In the absence of a submission from the holder of the marketing authorisation.

fosamprenavir (Telzir) in combination with low dose ritonavir is not recommended for use within NHSScotland for the treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infected adolescents and children of 6 years and above in combination with other antiretroviral medicinal products.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Download detailed advice24KB (PDF)

Download

Medicine details

Medicine name:
fosamprenavir (Telzir)
SMC ID:
431/07
Indication:
for the treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infected adolescents and children of 6 years and above in combination with other antiretroviral medicinal products
Pharmaceutical company
GlaxoSmithKline UK Ltd
BNF chapter
Infections
Submission type
Non submission
Status
Not recommended
Date advice published
10 December 2007